September 2008 Editor's Picks: Products from LiquaJet and Yokogawa - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

September 2008 Editor's Picks: Products from LiquaJet and Yokogawa


Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

product LiquaJet
Technology mills resistant materials

LiquaJet (Moorestown, NJ), a new company created by the Jet Pulverizer Company (Moorestown), offers jet-milling services based on a new, proprietary technology. The technology uses high-purity compressed liquid nitrogen rather than compressed gas. The compressed liquid nitrogen expands after entering the jet-milling chamber and provides greater pressure and force than compressed gas does.

The process mills materials that were previously ungrindable. For example, the technology grinds plastic and polymers that could previously be reduced to 100–200 µm to less than 30 µm, according to the company.

The LiquaJet technology contains no moving parts, prevents contamination, and does not create additional heat. The technology minimizes material loss and produces high yields that comply with good manufacturing practices. The company is inspected by the US Food and Drug Administration.



productYokogawa Corporation of America
Production-control system has new features

Yokogawa Corporation of America (Newnan, GA) has added pharmaceutical batch-control capabilities to its “Centum VP” integrated production-control system. New features include recipe-management and process-management functions in addition to the application’s unit-supervision and process-control tools.

The Centum VP software now provides a configurable unit faceplate that lets users monitor and execute batches through an interface. The application also features standard displays for product overview, product control, and unit control for recipe and product selection. The displays offer automatic, current documentation of the batch logic.

In addition, the software separates recipe data from equipment data and provides unit-based exception handling. The latter function allows batch engineers to create modular procedures for main production activities, engineer exception handling through unit monitors, and interrupt processing if necessary. Thus, automation engineers can execute failure-handling logic one time, rather than during each phase of production.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
14%
To select process for new products only
23%
To select processes for both new and legacy products
20%
Do not use QbD
25%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
FindPharma Custom Search
Source: Equipment and Processing Report,
Click here